Fennec Pharmaceuticals Inc (FRX.TO) saw a notable increase in its stock price, closing up 2.00% in the last trading session.
Fennec Pharmaceuticals Inc is making waves on the TSX, with its stock rising by 2.00% to close at CA$14.79. This uptick comes as the company continues to build on its recent successes in the pharmaceutical sector, particularly with its flagship product, PEDMARK®.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$484.58M
52W high
$15.48
52W low
$7.59
1W change
-0.72%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 575.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+575.6% Upside
Current Price
C$13.85
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
48.5%
Annualized
90-Day Vol
82.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.70 | C$12.44 – C$17.37 |
| 60 trading days | C$15.60 | C$12.32 – C$19.76 |
| 90 trading days | C$16.56 | C$12.39 – C$22.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on Fennec Pharmaceuticals as it capitalizes on strong sales growth and positive clinical developments, which could further enhance its market position.
Market Cap Reaches CA$503.7 Million
With a market cap of CA$503.7 million, Fennec Pharmaceuticals is positioning itself as a key player in the pharmaceutical landscape, particularly with its innovative products.
Bull case
Fennec Pharmaceuticals is showing strong growth, with product sales increasing significantly year-over-year. The recent financial results reflect this positive trend, and the successful equity offering indicates that investors are confident in the company's future.
Bear case
Despite the positive momentum, Fennec Pharmaceuticals is still operating at a loss. Any downturns in product demand or setbacks in clinical trials could negatively affect its stock performance.
Strong Sales Growth
Advertisement
Fennec Pharmaceuticals has reported impressive sales figures, with net PEDMARK® product sales reaching CA$44.6 million, marking a 50% increase year-over-year. This growth is a key driver behind the stock's rise, as investors respond positively to the company's expanding market presence.
Investor Confidence
The company recently completed an oversubscribed equity offering, raising CA$42 million. This move not only strengthens its financial position but also signals to investors that confidence in Fennec's future is high. As the company continues to innovate and expand, this confidence may translate into further stock performance gains.
Looking Ahead
With ongoing clinical studies and a focus on expanding its product offerings, Fennec Pharmaceuticals is poised for continued growth. Investors should monitor upcoming news and developments closely, as they could significantly impact stock performance. For more insights on Fennec Pharmaceuticals, visit our FRX.TO stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
